Evidence map›Paper›PMID 42855480›Full record

Reviewnpj drug discovery2026

TechBio 3.0 closes the drug discovery loop with multimodal AI and generative chemistry.

Krish Ramadurai, Abhirup Banerjee

Abstract readReview
PubMed Publisher
In one paragraph

Review in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Krish RamaduraiInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK. krish.ramadurai@st-hildas.ox.ac.uk.ORCID http://orcid.org/0009-0001-5723-5316
Abhirup BanerjeeInstitute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-8198-5128

Funding

Royal Society University Research Fellowship URF\R1\221314
6 · The paper itself

Abstract

Artificial intelligence (AI) has transformed molecular prediction and design, yet these advances remain only partially integrated with experimental discovery. We define TechBio 3.0 as an emerging paradigm for closed-loop drug discovery that connects multimodal molecular representations, generative chemistry, and automated experimentation. We examine its early preclinical and clinical evidence, identify remaining technical and translational barriers, and argue that this convergence is beginning to define biotechnology's next era.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.